Search clinical trials for: bococizumab (PF-04950615)

Total 1298 results

Pfizer

Completed

Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

Hypercholesterolemia

United States
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins (SPIRE-SI)

Hyperlipidemia

United States, Canada
Pfizer

Completed

Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

Hypercholesterolemia

United States
Pfizer

Terminated

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

Cardiovascular Disease

Finland, United States, Netherlands, Spain, Korea, Republic of, China, Israel, Belgium, Germany, Australia, Czechia, Taiwan, Denmark, United Kingdom, Hungary, Poland, France, Mexico, Turkey, Canada, New Zealand, Colombia, Switzerland, Irelan... and more
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-LL)

Hyperlipidemia

Finland, Netherlands, United States, Canada, Sweden, Korea, Republic of, Singapore, Czechia, Poland, United Kingdom, Puerto Rico, Norway
Pfizer

Terminated

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2)

Cardiovascular Disease

United States, Finland, Netherlands, Spain, Belgium, Germany, Czechia, Switzerland, Denmark, Australia, United Kingdom, Korea, Republic of, Hungary, Israel, Poland, Taiwan, Mexico, Turkey, Ireland, Canada, New Zealand, South Africa, Brazi... and more
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events (SPIRE-LDL)

Hyperlipidemia

United States, Spain, Taiwan, United Kingdom, Canada, Mexico, France, Hungary, Lithuania, Colombia, Romania, Russian Federation
Pfizer

Completed

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia (SPIRE-FH)

Heterozygous Familial Hypercholesterolemia

Canada, Netherlands, United Kingdom, United States, Spain, Poland, Finland, Norway, South Africa, Italy, Bulgaria
Pfizer

Completed

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-HR)

Hyperlipidemia

Korea, Republic of, United States, Australia, Germany, Poland, Canada, Italy, Hong Kong, Czech Republic
Pfizer

Completed

Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

Hypercholesterolemia

Japan
Pfizer

Completed

A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias

United States
University of California, San Francisco
Pfizer; San Francisco General Hospital

Terminated

Bococizumab HIV Evaluation (B-HIVE) Study (B-HIVE)

Cardiovascular Disease | Dyslipidemia

United States
Pfizer

Completed

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

Dyslipidemia | Hypercholesterolemia

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

Hypercholesterolemia

United States
Pfizer

Completed

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

Dyslipidemia | Hypercholesterolemia

United States, Canada
Pfizer

Completed

Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin

Dyslipidemia | Hypercholesterolemia

United States
Pfizer

Completed

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

Dyslipidemia | Hypercholesterolemia

United States, Canada
Pfizer

Completed

Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia (SPIRE-AI)

Hyperlipidemia

United States
Pfizer

Completed

Single Dose Manufacturing Site (Pfizer vs. BIP) And Device (Prefilled Syringe vs. Prefilled Pen) Comparability Study For Bococizumab In Healthy Volunteers

Healthy

United States
Pfizer
Halozyme Therapeutics

Terminated

Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase

Healthy | Hypercholesterolemia

Belgium
Kadmon Corporation, LLC

Completed

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Cancer

United States
Pfizer

Completed

To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity

Healthy

United Kingdom
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
Pfizer

Completed

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

Healthy

United States
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
University of Florida

Completed

Potato Fiber and Gastrointestinal Function: Phase 3

Gastrointestinal Symptoms | Stool Frequency | Gastrointestinal Transit Time

United States
Pfizer

Completed

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Healthy

United States
Pfizer

Completed

A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955

Healthy

United States
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

Healthy

United States
Pfizer

Recruiting

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Pfizer

Withdrawn

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects (A7881006)

Respiratory Tract Diseases | Bronchial Diseases | Lung Diseases, Obstructive | Asthma, Bronchial
Pfizer

Completed

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis With Liver Fibrosis

Hong Kong, United States, Taiwan, Puerto Rico, China, Canada, Korea, Republic of, Bulgaria, Japan, India, Poland, Slovakia
Pfizer

Completed

A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men

Healthy Participants

Netherlands
Pfizer

Completed

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

Healthy Participants

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

Healthy

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Healthy

United States
Pfizer

Withdrawn

A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals

Healthy
Pfizer

Terminated

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

Healthy

United States
Pfizer

Completed

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

Healthy | Chronic Rhinosinusitis With Nasal Polyps | Atopic Dermatitis

United States
Pfizer

Completed

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Psoriasis

Canada, United States, Japan, Poland
Pfizer

Completed

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Completed

A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Completed

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

Endometriosis

United States, Belgium
Pfizer

Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Healthy Participants

United States, Belgium
Pfizer

Active, not recruiting

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Renal Cell Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bile Duct Cancer | Endometrial Cancer | Urothelial Cancer | Lung Squamous Cell Carcinoma | Melanoma Cancer

United States, Taiwan, Korea, Republic of, Australia, Slovakia

3

Subscribe